Posts Tagged ‘atrial fibrillation’

Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study

The actual consequence of suboptimal anticoagulation management in patients with nonvalvular atrial fibrillation (NVAF) is unclear in the real-life practice.

Esther W. Chan PhD, Wallis C.Y. Lau BSc, Chung Wah Siu MD, Gregory Y.H. Lip MD, Wai K. Leung MD, Shweta Anand BDS, Kenneth K.C. Man MPH and Ian C.K. Wong PhD
Heart Rhythm, 2016-08-01, Volume 13, Issue 8, Pages 1581-1588, Copyright © 2016 Heart Rhythm Society

Relationships between anticoagulation regimen, risk score and adverse outcomes in dialysis patients with atrial fibrillation

Atrial fibrillation (AF) is the commonest cardiac arrhythmia including in end-stage renal failure patients, and there is increasing evidence that anticoagulation leads to more harm than benefit in these patients on dialysis. We reviewed the characteristics, management and outcomes of end-stage renal failure patients in dialysis with AF with a focus on warfarin anticoagulation and risk scores.

T. Wang, J. Sathananthan, C. Hood, G. Gamble, M. Marshall, A. Kerr
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

AV junction ablation audit – Auckland City Hospital

Atrio-ventricular junction (AVJ) ablation remains a strategy for patients with symptomatic atrial fibrillation (AF). We evaluated demographics and procedural outcomes in a contemporary series of patients undergoing AVJ ablation at our institution.

J. Voss, L. Maher, C. Jones, N. Lever
Auckland City Hospital, Auckland
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

The Australian experience of government subsidisation of novel oral anticoagulants (NOACs) Online Only

NOACs offer physicians an alternative to warfarin for stroke prevention in atrial fibrillation (AF). The Pharmaceutical Benefits Scheme (PBS) is the system whereby the Australian Government subsidises medications for defined indications. Initially NOACs were only subsidised for specific venous thromboembolism treatment and prevention indications. Authorities to prescribe NOACs for prevention of stroke in at-risk patients with AF were added to the PBS in August 2013 for rivaroxaban, and September 2013 for apixaban and dabigatran.

A. Vlachadis Castles, W. van Gaal
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Are guidelines adhered to at first assessment of atrial fibrillation

Nurse led atrial fibrillation (AF) clinics have been reported to improve adherence to guidelines and improve clinical outcome. In order to assess the potential for this approach to improve patient care locally an audit of current AF management was conducted.

I. Melton, L. Lim
Christchurch Hospital, Christchurch
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Cryoablation for AF in the Waikato; Early results

Cryoablation is a novel treatment for atrial fibrillation (AF). Commencing November 2012 with 3 operators (2 AF ablation novices), cryoablation has been performed in patients with paroxysmal AF and selected persistent AF cases. We retrospectively assessed all cryoablation patients treated over the first 14 months.

E. Kooijman, I. Grey, R. Allen, S. Heald, D. Boddington, M. Stiles
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Low prevalence of left atrial thrombus detected by transoesphageal echocardiogram in patients with arrhythmia prior to DC cardioversion

Patients requiring acute DC cardioversion (DCCV) for atrial fibrillation (AF) or flutter (AFlt) require exclusion of left atrial appendage (LAA) thrombus to reduce their risk of stroke. Transoesophageal echocardiography (TOE) is the gold standard modality but is invasive. Cardiac CT has a high negative predictive value for LA thrombus and is potentially an alternative to TOE in this population. We studied the prevalence of LAA thrombus and spontaneous echo contrast (SEC) in patients who required acute DCCV to determine the feasibility of using CT in this setting.

D. Hare, A. Pope, S. Kueh, J. Looi, N. van Pelt, R. Gabriel
Department of Cardiology, Middlemore Hospital, Auckland
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Pre-operative atrial fibrillation is independently associated with short and long-term mortality after aortic valve replacement

Atrial fibrillation (AF) is the commonest cardiac arrhythmia, becoming increasing prevalent as the population ages, and is an important risk factor for stroke. There are conflicting results around whether AF is associated with adverse outcomes after aortic valve replacement (AVR) amongst the few studies that have investigated this. We compared the characteristics and outcomes of patients undergoing AVR by history of AF.

T. Wang, D. Choi, T. Ramanathan, P. Ruygrok
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Interested in joining CSANZ?